RAPP (Rapport Therapeutics) Retained Earnings: $-255.09 Mil (As of Mar. 2026)


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics Retained Earnings?

Rapport Therapeutics RAPP -0.60% 14 Retained Earnings is $-255.09 Mil as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review.

Retained earnings is the accumulated portion of net income that is not distributed to shareholders. Rapport Therapeutics's retained earnings for the quarter that ended in Mar. 2026 was $-255.09 Mil.

Rapport Therapeutics's quarterly retained earnings declined from Sep. 2025 ($-201.47 Mil) to Dec. 2025 ($-235.23 Mil) and declined from Dec. 2025 ($-235.23 Mil) to Mar. 2026 ($-255.09 Mil).

Rapport Therapeutics's annual retained earnings declined from Dec. 2023 ($-45.44 Mil) to Dec. 2024 ($-123.75 Mil) and declined from Dec. 2024 ($-123.75 Mil) to Dec. 2025 ($-235.23 Mil).

Rapport Therapeutics  (NAS:RAPP) Retained Earnings Explanation

Historically profitable companies sometimes have negative retained earnings. This is because they have cumulatively paid out more to shareholders than they reported in profits.

For example, in 2011, Microsoft had negative retained earnings. This does not mean the company lost more money than it made over the years. It just means it paid out more money than it earned.

If a company has negative retained earnings, investors should check the 10-year financial results. They should not assume that negative retained earnings prove a company has generally lost money in the past.

Of course, many companies with negative retained earnings have indeed lost money in the past.

Retained Earnings: Warren Buffett's Secret.

One of the most important indicators of durable competitive advantage. Net earnings can be paid out as dividends, used to buy back shares or retained for growth.

If the company loses more than it has accumulated, retained earnings is negative.

If a company isn't adding to its retained earnings, it isn't growing its net worth.

Rate of growth of retained earnings is good indicator whether it's benefiting from a competitive advantage.

Microsoft is negative because it chose to buyback stock and pay dividends.

The more earnings retained, the faster it grows and increases growth rate for future earnings.

Rapport Therapeutics Retained Earnings Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's Retained Earnings can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics Retained Earnings Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Retained Earnings
-10.65 -45.44 -123.75 -235.23

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Retained Earnings Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -147.81 -174.54 -201.47 -235.23 -255.09
RAPP
14GF Score
Rapport Therapeutics Inc RAPP
Retained Earnings is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics Retained Earnings Calculation

Retained Earnings is the accumulated portion of net income that is not distributed to shareholders. Because the net income was not distributed to shareholders, shareholders' equity is increased by the same amount.

Of course, if a company loses, it is called retained losses, or accumulated losses.

Frequently Asked Questions Learn more about Retained Earnings →
What does a Retained Earnings of $-255.09 Mil mean?
Rapport Therapeutics (RAPP) has a Retained Earnings of $-255.09 Mil as of Mar. 2026. Retained earnings is the amount of net income not issued to shareholders. View historical data on Rapport Therapeutics and its competitors.
Is Rapport Therapeutics' Retained Earnings too high?
Rapport Therapeutics' current Retained Earnings is $-255.09 Mil. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' Retained Earnings compare to SION and TYRA?
Rapport Therapeutics' Retained Earnings of $-255.09 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Retained Earnings for a Biotechnology company?
A good Retained Earnings depends on the Biotechnology industry context. However, Retained Earnings should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Retained Earnings mean?
A high Retained Earnings can signal that a stock is expensive relative to its fundamentals. Retained earnings is the amount of net income not issued to shareholders. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current Retained Earnings is $-255.09 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current Retained Earnings of $-255.09 Mil. The current Retained Earnings is $-255.09 Mil. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Retained Earnings calculated?
Retained Earnings is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current Retained Earnings is $-255.09 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

Retained Earnings is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price